新鬼武者パチスロ

2022年

November 9, 2022: Summary of Consolidated Financial Results(For the second quarter ended September 30, 2022) [Japanese Standard]
November 9, 2022: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary 新鬼武者パチスロ
November 9, 2022: 新鬼武者パチスロ and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
August 2, 2022: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
August 2, 2022: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary 新鬼武者パチスロ
August 2, 2022: Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
June 17, 2022: 新鬼武者パチスロ Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022: Notice of Resumption of Operation at Nishinihon Delivery Center
May 11, 2022: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
May 11, 2022: Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary 新鬼武者パチスロ
May 11, 2022: Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　KYORIN Pharmaceutical 新鬼武者パチスロ., Ltd., Change of Trade Name and Partial Amendment to Articles of Incorporation
May 11, 2022: Notice of Reduction of Capital Reserve
April 26, 2022: Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
April 20, 2022: NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of cough "Lyfnua® Tablet 45 mg"
March 30, 2022: 新鬼武者パチスロ and Lumen Bioscience Reach Collaboration Research Agreement
March 17, 2022: 新鬼武者パチスロ and Nanjing Neiwa Faith Signed License Agreement for Lascufloxacin in China
February 24, 2022: Construction of the Takaoka New Plant by a Subsidiary Company
February 4, 2022: Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]
February 4, 2022: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary 新鬼武者パチスロ
February 4, 2022: Notice of Merger Preparations at Consolidated Subsidiary, KYORIN Pharmaceutical 新鬼武者パチスロ., Ltd.
January 20, 2022: MSD K.K. receives manufacturing and marketing approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough
January 17, 2022: 新鬼武者パチスロ-promotion agreement in Japan for oral COVID-19 treatment LAGEVRIO Capsules 200 mg

1